采用石墨炉原子吸收光谱法测定人血浆和血浆超滤液中的奥沙利铂。

Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry.

作者信息

Brouwers E E M, Tibben M M, Joerger M, van Tellingen O, Rosing H, Schellens J H M, Beijnen J H

机构信息

Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands.

出版信息

Anal Bioanal Chem. 2005 Aug;382(7):1484-90. doi: 10.1007/s00216-005-3302-5. Epub 2005 Jun 11.

DOI:10.1007/s00216-005-3302-5

PMID:15952001

Abstract

A method for sensitive determination of the anti-cancer agent oxaliplatin in human plasma and human plasma ultrafiltrate (pUF) is presented. The method is based on the quantification of platinum by graphite-furnace atomic-absorption spectrometry, with Zeeman correction and an atomisation temperature of 2,700 degrees C. Sample pretreatment involves dilution of the samples with a solution containing 0.15 mol L(-1) NaCl and 0.20 mol L(-1) HCl in water. Validation was performed in accordance with the most recent FDA guidelines for bioanalytical method validation. All results were within requirements. The validated ranges of quantification were 0.10-400 micromol L(-1) for human pUF and 0.50-400 micromol L(-1) for plasma. The assay is now successfully used to support pharmacokinetic studies of cancer patients treated with oxaliplatin.

摘要

本文介绍了一种灵敏测定人血浆和人血浆超滤液（pUF）中抗癌药物奥沙利铂的方法。该方法基于采用塞曼校正且原子化温度为2700℃的石墨炉原子吸收光谱法对铂进行定量。样品预处理包括用含有0.15 mol L⁻¹氯化钠和0.20 mol L⁻¹盐酸的水溶液稀释样品。按照美国食品药品监督管理局（FDA）生物分析方法验证的最新指南进行了验证。所有结果均符合要求。人pUF的验证定量范围为0.10 - 400 μmol L⁻¹，血浆的验证定量范围为0.50 - 400 μmol L⁻¹。该测定法现已成功用于支持接受奥沙利铂治疗的癌症患者的药代动力学研究。